Safety and efficacy of remote electrical neuromodulation for the acute treatment of chronic migraine: an open-label study. (14th November 2021)

• Record Type: Journal Article
• Authors: Grosberg, Brian; Rabany, Liron; Lin, Tamar; Harris, Dagan; Vizel, Maya; Ironi, Alon; O'Carroll, Christopher P.; Schim, Jack
• Is Part Of: Pain reports. Volume 6:Number 4(2021)
• Page Start: e966
• Publication Date: 2021-11-14
• Subjects: Conditioned pain modulation -- Medication overuse headache -- REN -- Nerivio -- Nonpharmacological
• DOI: 10.1097/PR9.0000000000000966
• Languages: English
• ISSNs: 2471-2531

Abstract

Abstract : Supplemental Digital Content is Available in the Text. The efficacy of REN was evaluated in patients with chronic migraine. Pain relief was achieved in 59.3% of participants and pain disappearance in 20.9% (2 hours posttreatment). Abstract: Introduction: Remote electrical neuromodulation (REN) is an acute treatment of migraine. The results from several studies in patients with episodic migraine suggest that REN is an effective and safe acute treatment of migraine. A recent pilot study provided initial support that REN is effective in patients with chronic migraine as well. Objectives: The current study aimed to validate and provide further evidence for the safety and efficacy of REN in a large sample of patients impacted by chronic migraine. Methods: In this open-label, single-arm study, patients with chronic migraine treated their headaches with the REN device (Nerivio, Theranica Bio-Electronics Ltd, Israel) for 4 weeks. Participants used an electronic diary to record their symptoms at treatment initiation, 2 hours after treatment, and 24 hours after treatment. The primary end point was the percentage of subjects who achieved pain relief at 2 hours posttreatment. Secondary end points included pain freedom and improvement of associated symptoms and functional disability. Results: One hundred twenty-six subjects were enrolled into the study, of which 91 subjects had an evaluable treatment with REN. Pain relief and pain disappearance at 2 hours were achieved by 59.3% (54/91) and 20.9% (19/91) of modified intent-to-treat subjects, respectively (with worst-case sensitivity analysis indicating 54.5% and 19.2%, respectively). Sustained pain relief at 24 hours was observed in 64.4% (29/45) of those who achieved pain relief at 2 hours (with worst-case sensitivity analysis indicating 45.6%). The findings of the study show that REN has a favorable effect on nausea, photophobia, and phonophobia and improves functional ability. One device-related adverse event was reported. Conclusions: Remote electrical neuromodulation treatments results in the relief of migraine headaches and associated symptoms, thus offering a drug-free acute treatment option for people with chronic migraine. Trial registration: ClinicalTrials.gov NCT04194008.